• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
The Washington State Hub and Spoke Model to increase access to medication treatment for opioid use disorders.华盛顿州中心辐射模型,以增加获得阿片类药物使用障碍药物治疗的机会。
J Subst Abuse Treat. 2020 Jan;108:33-39. doi: 10.1016/j.jsat.2019.07.007. Epub 2019 Jul 19.
2
Preliminary results of the evaluation of the California Hub and Spoke Program.加利福尼亚轴心辐射计划评估的初步结果。
J Subst Abuse Treat. 2020 Jan;108:26-32. doi: 10.1016/j.jsat.2019.07.014. Epub 2019 Aug 1.
3
Implementation and evaluation of Missouri's Medication First treatment approach for opioid use disorder in publicly-funded substance use treatment programs.在公立药物滥用治疗项目中实施和评估密苏里州的药物优先治疗阿片类药物使用障碍的方法。
J Subst Abuse Treat. 2020 Jan;108:55-64. doi: 10.1016/j.jsat.2019.06.015. Epub 2019 Jun 26.
4
Implementation of the hub and spoke model for opioid use disorders in California: Rationale, design and anticipated impact.加利福尼亚州阿片类药物使用障碍的中心辐射模型的实施:基本原理、设计和预期影响。
J Subst Abuse Treat. 2020 Jan;108:20-25. doi: 10.1016/j.jsat.2019.07.013. Epub 2019 Jul 27.
5
The case for a medication first approach to the treatment of opioid use disorder.采用药物优先治疗阿片类药物使用障碍。
Am J Drug Alcohol Abuse. 2019;45(4):333-340. doi: 10.1080/00952990.2019.1605372. Epub 2019 May 14.
6
Patient perceptions of treatment with medication treatment for opioid use disorder (MOUD) in the Vermont hub-and-spoke system.患者对佛蒙特州中心辐射式系统中使用药物治疗阿片类药物使用障碍(MOUD)的治疗感受。
Prev Med. 2019 Nov;128:105785. doi: 10.1016/j.ypmed.2019.105785. Epub 2019 Jul 27.
7
The Community-Based Medication-First program for opioid use disorder: a hybrid implementation study protocol of a rapid access to buprenorphine program in Washington State.基于社区的药物优先治疗阿片类药物使用障碍项目:华盛顿州快速获得丁丙诺啡项目的混合实施研究方案。
Addict Sci Clin Pract. 2022 Jul 7;17(1):34. doi: 10.1186/s13722-022-00315-4.
8
State-Targeted Funding and Technical Assistance to Increase Access to Medication Treatment for Opioid Use Disorder.针对目标的资金投入和技术援助,以增加阿片类药物使用障碍药物治疗的可及性。
Psychiatr Serv. 2018 Apr 1;69(4):448-455. doi: 10.1176/appi.ps.201700196. Epub 2017 Dec 15.
9
State targeted response to the opioid Crisis grants (opioid STR) program: Preliminary findings from two case studies and the national cross-site evaluation.针对阿片类药物危机的州级有针对性反应拨款(opioid STR)项目:两项案例研究和全国跨站点评估的初步发现。
J Subst Abuse Treat. 2020 Jan;108:48-54. doi: 10.1016/j.jsat.2019.06.008. Epub 2019 Jun 11.
10
Expanding access to medication treatment for opioid use disorders: Findings from the Washington State hub and spoke effort.扩大阿片类药物使用障碍药物治疗的机会:华盛顿州中心辐射努力的结果。
Drug Alcohol Depend. 2024 Mar 1;256:111125. doi: 10.1016/j.drugalcdep.2024.111125. Epub 2024 Feb 14.

引用本文的文献

1
Effectiveness of Washington State's hub and spoke model to improve opioid use disorder outcomes.华盛顿州枢纽辐射模式改善阿片类药物使用障碍治疗效果的有效性。
Health Aff Sch. 2025 Aug 7;3(8):qxaf157. doi: 10.1093/haschl/qxaf157. eCollection 2025 Aug.
2
The linkage between opioid treatment programs and recovery community centers: results of a survey of OTP directors.阿片类药物治疗项目与康复社区中心之间的联系:对阿片类药物治疗项目主任的调查结果
Front Public Health. 2025 Aug 7;13:1532374. doi: 10.3389/fpubh.2025.1532374. eCollection 2025.
3
Establishment of a New Retinal Service in Remote Western Australia: Kimberley Hub-A Comparative Audit 2019-2022.西澳大利亚偏远地区新视网膜服务的建立:金伯利中心——2019 - 2022年比较审计
Aust J Rural Health. 2025 Feb;33(1):e13217. doi: 10.1111/ajr.13217.
4
Perspectives of substance use disorder counselors on the benefits and drawbacks of medications for opioid use disorder.物质使用障碍咨询师对阿片类物质使用障碍药物治疗利弊的看法。
Addict Sci Clin Pract. 2025 Feb 4;20(1):7. doi: 10.1186/s13722-025-00537-2.
5
Patient centered medication treatment for opioid use disorder in rural Vermont: a qualitative study.佛蒙特州农村地区以患者为中心的阿片类药物使用障碍药物治疗:一项定性研究
Addict Sci Clin Pract. 2025 Jan 14;20(1):3. doi: 10.1186/s13722-024-00529-8.
6
Relationship of hub and treatment characteristics with client outcomes in the initial Washington State hub and spoke cohort.华盛顿州首个枢纽与辐条式队列研究中枢纽及治疗特征与客户结局的关系。
J Subst Use Addict Treat. 2025 Jan;168:209544. doi: 10.1016/j.josat.2024.209544. Epub 2024 Oct 20.
7
Using 42 CFR part 2 revisions to integrate substance use disorder treatment information into electronic health records at a safety net health system.利用 42 CFR 第 2 部分修订版,将物质使用障碍治疗信息整合到一个安全网健康系统的电子健康记录中。
Addict Sci Clin Pract. 2024 Jun 7;19(1):48. doi: 10.1186/s13722-024-00477-3.
8
Perspectives of substance use disorder counselors on the benefits and drawbacks of medications for opioid use disorder.物质使用障碍咨询师对阿片类物质使用障碍药物治疗的利弊看法
Res Sq. 2024 May 3:rs.3.rs-4331201. doi: 10.21203/rs.3.rs-4331201/v1.
9
Federal Impacts on Buprenorphine Prescribing in Washington State, 2012 to 2022.2012 年至 2022 年联邦政府对华盛顿州丁丙诺啡处方的影响。
Am J Public Health. 2024 Jul;114(7):696-704. doi: 10.2105/AJPH.2024.307649. Epub 2024 May 2.
10
Expanding access to medication treatment for opioid use disorders: Findings from the Washington State hub and spoke effort.扩大阿片类药物使用障碍药物治疗的机会:华盛顿州中心辐射努力的结果。
Drug Alcohol Depend. 2024 Mar 1;256:111125. doi: 10.1016/j.drugalcdep.2024.111125. Epub 2024 Feb 14.

本文引用的文献

1
Development of a Cascade of Care for responding to the opioid epidemic.开发一个应对阿片类药物流行的护理级联。
Am J Drug Alcohol Abuse. 2019;45(1):1-10. doi: 10.1080/00952990.2018.1546862. Epub 2019 Jan 24.
2
Assessment of medication for opioid use disorder as delivered within the Vermont hub and spoke system.评估佛蒙特州中心辐射系统中提供的阿片类药物使用障碍治疗药物。
J Subst Abuse Treat. 2019 Feb;97:84-90. doi: 10.1016/j.jsat.2018.11.003. Epub 2018 Nov 19.
3
Cost-Effectiveness of Buprenorphine-Naloxone Versus Extended-Release Naltrexone to Prevent Opioid Relapse.丁丙诺啡-纳洛酮与纳曲酮长效制剂预防阿片类药物复吸的成本效益比较。
Ann Intern Med. 2019 Jan 15;170(2):90-98. doi: 10.7326/M18-0227. Epub 2018 Dec 18.
4
Prevention and Treatment of Opioid Misuse and Addiction: A Review.阿片类药物滥用和成瘾的预防和治疗:综述。
JAMA Psychiatry. 2019 Feb 1;76(2):208-216. doi: 10.1001/jamapsychiatry.2018.3126.
5
Moving Addiction Care to the Mainstream - Improving the Quality of Buprenorphine Treatment.将成瘾治疗纳入主流——提高丁丙诺啡治疗质量
N Engl J Med. 2018 Jul 5;379(1):4-6. doi: 10.1056/NEJMp1804059.
6
Treatment and Prevention of Opioid Use Disorder: Challenges and Opportunities.阿片类药物使用障碍的治疗和预防:挑战与机遇。
Annu Rev Public Health. 2018 Apr 1;39:525-541. doi: 10.1146/annurev-publhealth-040617-013526. Epub 2017 Dec 22.
7
Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.长效纳曲酮与丁丙诺啡-纳洛酮预防阿片类药物复发的比较效果(X:BOT):一项多中心、开放标签、随机对照试验。
Lancet. 2018 Jan 27;391(10118):309-318. doi: 10.1016/S0140-6736(17)32812-X. Epub 2017 Nov 14.
8
Prescribing patterns of buprenorphine waivered physicians.有资格开丁丙诺啡的医师的处方模式。
Drug Alcohol Depend. 2017 Dec 1;181:213-218. doi: 10.1016/j.drugalcdep.2017.10.002. Epub 2017 Oct 18.
9
Primary care models for treating opioid use disorders: What actually works? A systematic review.治疗阿片类药物使用障碍的初级保健模式:实际有效的方法是什么?一项系统综述。
PLoS One. 2017 Oct 17;12(10):e0186315. doi: 10.1371/journal.pone.0186315. eCollection 2017.
10
Barriers to Medications for Addiction Treatment: How Stigma Kills.成瘾治疗药物的障碍:耻辱感如何致人死亡。
Subst Use Misuse. 2018 Jan 28;53(2):330-333. doi: 10.1080/10826084.2017.1363238. Epub 2017 Sep 29.

华盛顿州中心辐射模型,以增加获得阿片类药物使用障碍药物治疗的机会。

The Washington State Hub and Spoke Model to increase access to medication treatment for opioid use disorders.

机构信息

Institute for Behavioral Health, Heller School for Social Policy and Management, Brandeis University, 415 South Street, Waltham, MA 02453, USA.

Institute for Behavioral Health, Heller School for Social Policy and Management, Brandeis University, 415 South Street, Waltham, MA 02453, USA.

出版信息

J Subst Abuse Treat. 2020 Jan;108:33-39. doi: 10.1016/j.jsat.2019.07.007. Epub 2019 Jul 19.

DOI:10.1016/j.jsat.2019.07.007
PMID:31358328
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6893117/
Abstract

INTRODUCTION

The federal Opioid State Targeted Response (Opioid STR) grants provided funding to each state to ramp up the range of responses to reverse the ongoing opioid crisis in the U.S. Washington State used these funds to develop and implement an integrated care model to expand access to medication treatment and reduce unmet need for people with opioid use disorders (OUD), regardless of how they enter the treatment system. This paper examines the design, early implementation and results of the Washington State Hub and Spoke Model.

METHODS

Descriptive data were gathered from key informants, document review, and aggregate data reported by hubs and spokes to Washington State's Opioid STR team.

RESULTS

The Washington State Hub and Spoke Model reflects a flexible approach that incorporates primary care and substance use treatment programs, as well as outreach, referral and social service organizations, and a nurse care manager. Hubs could be any type of program that had the required expertise and capacity to lead their network in medication treatment for OUD, including all three FDA-approved medications. Six hub-spoke networks were funded, with 8 unique agencies on average, and multiple sites. About 150 prescribers are in these networks (25 on average). In the first 18 months, nearly 5000 people were inducted onto OUD medication treatment: 73% on buprenorphine, 19% on methadone, and 9% on naltrexone.

CONCLUSIONS

The Washington State Hub and Spoke Model built on prior approaches to improve the delivery system for OUD medication treatment and support services, by increasing integration of care, ensuring "no wrong door," engaging with community agencies, and supporting providers who are offering medication treatment. It used essential elements from existing integrated care OUD treatment models, but allowed for organic restructuring to meet the population needs within a community. To date, there have been challenges and successes, but with this approach, Washington State has provided medication treatment for OUD to nearly 5000 people. Sustainability efforts are underway. In the face of the ongoing opioid crisis, it remains essential to develop, implement and evaluate novel models, such as Washington's Hub and Spoke approach, to improve treatment access and increase capacity.

摘要

简介

联邦阿片类药物州目标响应(Opioid STR)拨款为每个州提供资金,以扩大应对范围,扭转美国目前的阿片类药物危机。华盛顿州利用这些资金开发并实施了一种综合护理模式,以扩大药物治疗的可及性,并减少有阿片类药物使用障碍(OUD)的人的未满足需求,无论他们如何进入治疗系统。本文探讨了华盛顿州中心辐射模式的设计、早期实施和结果。

方法

从关键知情人、文件审查和中心和辐射点向华盛顿州阿片类药物 STR 团队报告的汇总数据中收集描述性数据。

结果

华盛顿州中心辐射模型反映了一种灵活的方法,其中包括初级保健和药物滥用治疗计划,以及外展、转介和社会服务组织,以及一名护士护理经理。中心可以是任何具有领导 OUD 药物治疗所需专业知识和能力的项目,包括所有三种经 FDA 批准的药物。六个中心辐射网络获得了资金,平均每个网络有 8 个独特的机构和多个地点。大约 150 名处方者在这些网络中(平均 25 名)。在最初的 18 个月里,近 5000 人接受了 OUD 药物治疗:73%的人使用丁丙诺啡,19%的人使用美沙酮,9%的人使用纳曲酮。

结论

华盛顿州中心辐射模型在先前改善 OUD 药物治疗和支持服务提供系统的方法基础上,通过增加护理的整合、确保“没有错误的门”、与社区机构合作以及支持提供药物治疗的提供者,进一步改进了方法。它利用了现有的综合护理 OUD 治疗模型的基本要素,但允许进行有机重组,以满足社区内的人口需求。迄今为止,该方法取得了一些挑战和成功,但通过这种方法,华盛顿州已经为近 5000 人提供了 OUD 药物治疗。可持续性工作正在进行中。面对持续的阿片类药物危机,开发、实施和评估新的模式仍然至关重要,例如华盛顿州的中心辐射方法,以改善治疗可及性并提高能力。